Cancer and myositis: New insights into an old association

Current Opinion in Rheumatology

Volumn 18, Issue 6, 2006, Pages 620-624

  Levine, Stuart M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Myositis; Paraneoplastic syndrome

Indexed keywords

AUTOANTIGEN;

ANTIGEN EXPRESSION; AUTOIMMUNITY; CANCER; CANCER TISSUE; CARCINOGENESIS; CELL REGENERATION; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; MUSCLE CELL; MUSCLE TISSUE; MYOPATHY; MYOSITIS; NERVOUS TISSUE; NONHUMAN; PARANEOPLASTIC SYNDROME; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW;

DERMATOMYOSITIS; HUMANS; MUSCLE, SKELETAL; NEOPLASMS; PARANEOPLASTIC SYNDROMES; POLYMYOSITIS;

EID: 33750205961     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000245721.02512.77     Document Type: Review

References (41)

1. Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54:597-613.
2. Callen JP. Myositis and malignancy. Curr Opin Rheumatol 1994; 6:590-594.
3. Yazici Y, Kagen LJ. The association of malignancy with myositis. Curr Opin Rheumatol 2000; 12:498-500.
4. Williams RC Jr. Dermatomyositis and malignancy: a review of the literature. Ann Intern Med 1959; 50:1174-1181.
5. Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 1976; 84:68-76.
6. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994; 21:1855-1859.
7. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995; 22:1300-1303.
8. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326:363-367.
9. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore) 1994; 73:153-160.
10. Ponyi A, Constantin T, Garami M, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann NY Acad Sci 2005; 1051:64-71.
11. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357:96-100.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344-347.
13. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292:403-407.
14. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134:1087-1095.
15. Amoura Z, Duhaut P, Huong du LT, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 2005; 14:1279-1282. This is the largest study to date examining the use of tumor markers to predict malignancy in patients with inflammatory myopathies. Based on this and other smaller studies, CA-125 levels should be checked yearly for at least 5 years after the diagnosis of myositis is made.
16. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123:1053-1055.
17. Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9:689-696.
18. Fishman P, Merimski O, Baharav E, Shoenfeld Y. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 1997; 79:1461-1464.
19. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372-8377.
20. Uchi H, Stan R, Turk MJ, et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. In: James PA, editor. Advances in immunology cancer immunotherapy, 90. USA: Academic Press; 2006. pp. 215-241.
21. Engelhorn ME, Guevara-Patino JA, Noffz G, et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006; 12:198-206. An important study showing how immune responses to altered self proteins in malignant cells can lead to autoimmunity in a melanoma model.
22. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 2004; 4:36-44.
23. Darnell JC, Albert ML, Darnell RB. Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 2000; 60:2136-2139.
24. Buckanovich RJ, Posner JB, Darnell RB. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 1993; 11:657-672.
25. Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996; 16:1114-1122.
26. Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322:1844-1851.
27. Dalmau J, Furneaux HM, Gralla RJ, et al. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - a quantitative western blot analysis. Ann Neurol 1990; 27:544-552.
28. Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21-22.
29. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42:1931-1937.
30. Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4:1321-1324.
31. Arnett FC, Hirsch TJ, Bias WB, et al. The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol 1981; 8:925-930.
32. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360-374.
33. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591-601. The first study to show that myositis tissue, regenerating muscle cells, and certain tumors selectively overexpress antigens that are targeted for an immune response in myositis.
34. Okada T, Noji S, Goto Y, et al. Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis. Int J Cancer 2005; 116:925-933. This study provides further evidence that common antigens are targeted for an immune response in myositis and certain histological tumor types.
35. Casciola-Rosen LA, Pluta AF, Plotz PH, et al. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001; 44:389-396.
36. Tallai B, Flasko T, Gyorgy T, et al. Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy. Clin Rheumatol 2006; 25:119-120.
37. Yoshinaga A, Hayashi T, Ishii N, et al. Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol 2005; 12:593-595.
38. Masuda H, Urushibara M, Kihara K. Successful treatment of dermatomyositis associated with adenocarcinoma of the prostate after radical prostatectomy. J Urol 2003; 169:1084.
39. Mori H, Habe K, Hakamada A, et al. Relapse of dermatomyositis after 10 years in remission following curative surgical treatment of lung cancer. J Dermatol 2005; 32:290-294.
40. Hengstman GJD, Vree Egberts WTM, Seelig HP, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2{beta} antigen. Ann Rheum Dis 2006; 65:242-245. An important study demonstrating that patients with cancer-associated myositis may target different epitopes of commonly targeted autoantigens (here Mi-2) than patients with myositis who do not develop a malignancy.
41. Howard OM, Dong HF, Yang D, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002; 196:781-791.